Staphylococcus Aureus Endocarditis
8
4
4
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
25.0%
2 terminated out of 8 trials
33.3%
-53.3% vs benchmark
75%
6 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (8)
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia